<i>In Vitro</i> Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates
Michael D. Huband, Rodrigo E. Mendes, Michael A. Pfaller, Jill Lindley, Gregory J. Strand, Vincent Benn, Jay Zhang, Li Li, Min Zhang, Xiaojuan Tan, Qingmei Liu, Robert K. Flamm
Abstract
KBP-7072 is a novel third-generation tetracycline (aminomethylcycline) antibacterial that overcomes common efflux and ribosomal protection resistance mechanisms that cause resistance in older-generation tetracyclines. KBP-7072 completed phase 1 clinical development studies for safety, tolerability, and pharmacokinetics (ClinicalTrials.gov identifier NCT02454361) and multiple ascending doses in healthy subjects (ClinicalTrials.gov identifier NCT02654626) in December 2015. Both oral and intravenous formulations of KBP-7072 are being developed.
Topics & Concepts
TetracyclineAcinetobacter baumanniiMicrobiologyThird generationBiologyAntibioticsGeneticsBacteriaPseudomonas aeruginosaComputer scienceTelecommunicationsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPharmaceutical and Antibiotic Environmental Impacts